One or two autografts for myeloma?

Blood

Volumn 111, Issue 7, 2008, Pages 3899-3900

  Merita, Jayesh ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; BUSULFAN; CYCLOPHOSPHAMIDE; LENALIDOMIDE; MELPHALAN; THALIDOMIDE;

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; DRUG MEGADOSE; EVENT FREE SURVIVAL; FOLLOW UP; HUMAN; LETTER; MAINTENANCE THERAPY; MYELOMA; NONMYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PRIORITY JOURNAL; TUNISIA; AUTOTRANSPLANTATION; CLINICAL TRIAL; FEMALE; MALE; MORTALITY; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION;

CLINICAL TRIALS AS TOPIC; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS;

EID: 43549083964     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-12-127704     Document Type: Letter

References (20)

1. Barlogie B, Tricot GJ. van Rhee F, et al. Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol. 2006;135:158-164.
2. Barlogie B, Jagannath S, Desikan KR, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood. 1999;93:55-65.
3. Mehta J, Singhal S. High-dose chemotherapy and autologous hematopoietic stem cell transplantation in myeloma patients under the age of 65 years. Bone Marrow Transplant. 2007;40:1101 -1114.
4. Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003;349:2495-2502.
5. Cavo M, Tosi P, Zamagni E, et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol. 2007;25:2434-2441.
6. Goldschmidt H. Single vs. double HDT in multiple myeloma: third analysis of the trial GMMG-HD2. 10th International Myeloma Workshop, Sydney, Australia, April 2005. http://myeloma.org/pdfs/Sydney2005-Goldschmidt-P8.pdf. Accessed December 2, 2006.
7. Fermand JP. MAG studies (1985-2005). 10th International Myeloma Workshop, Sydney, Australia, April 2005. http://myeloma.org/pdfs/Sydney2005-Fermand- P8.pdf. Accessed December 2, 2006
8. Sonneveld P, van der Holt B, Vellenga E, et al. Intensive versus double intensive therapy in untreated multiple myeloma: final analysis of the HOVON 24 trial. Blood. 2005; 106. Abstract 2545.
9. Abdelkefi A, Ladeb S, Torjman L, et al. Single autologous stem cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter ran-domized clinical trial. Blood. Prepublished on November 8, 2007, as DOI 10.1182/blood-2007-07-101212.
10. Fermand JP, Ravaud P, Chevret S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood. 1998;92:3131-3136.
11. Sirohi B. Powles R. Mehta J, et al. An elective single autograft with high-dose melphalan: single-center study of 451 patients. Bone Marrow Transplant. 2005; 36:19-24.
12. Blade J, Rosinol L, Sureda A, et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood. 2005;106: 3755-3759.
13. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Inter-groupe Francais du Myelome. N Engl J Med. 1996;335:91-97.
14. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348:1875-1883.
15. Palumbo A, Bringhen S, Petrucci MT, et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood. 2004;104:3052-3057.
16. Fermand JP, Katsahian S, Divine M, et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol. 2005;23:9227-9233.
17. Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet. 2007;370:1209-1218.
18. Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. 2006;354:1021-1030.
19. Attal M, Harousseau JL, Leyvraz S, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood. 2006;108: 3289-3294.
20. Barlogie B, Kyle RA, Anderson KC, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol. 2006;24:929-936.